This study demonstrates that human plasma a 2 -macroglobulin preparations possess an enzymic activity that degrades fibrinogen, resulting in the formation of products whose structure resembles that of circulating fibrinogen catabolites. The sequence of degradation is similar to that observed in plasmin-catalyzed digests, in that Aa-chain fragmentation precedes that of Bb-chain. The addition of plasminogen activators to plasma induced an increase in the N-a-tosyl-l-arginine methyl ester HCl esterase and fibrinogenolytic activity associated with a 2 -macroglobulin purified from this plasma, indicating that the enzymic activity of the complex was preserved and could be increased in the presence of other plasma enzyme inhibitors. Immunochemical studies demonstrated that an a 2 -macroglobulin-plasmin complex had formed in urokinase-treated plasma. This a 2 -macroglobulin preparation manifested an esterolytic profile like that of a complex prepared from plasmin and purified a 2 -macroglobulin. After complex formation with a 2 -macroglobulin in plasma, plasmin retained less than 0.1% of its fibrinogenolytic activity. That plasmin expressed its activity while bound to a 2 -macroglobulin was suggested by immunoprecipitation of this activity with a 2 -macroglobulin antibody and by the demonstration that pancreatic trypsin inhibitor did not effectively inhibit its fibrinogenolytic or esterolytic activity. These results raise the possibility that, in addition to its activity as a major plasma proteolytic enzyme inhibitor, a 2 -macroglobulin may modulate enzymesubstrate interactions, such as those resulting in the formation of circulating fibrinogen catabolites, by providing a mechanism for the [ A B S T R A C T This study demonstrates that human plasma a2-macroglobulin preparations possess an enzymic activity that degrades fibrinogen, resulting in the formation of products whose structure resembles that of circulating fibrinogen catabolites. The sequence of degradation is similar to that observed in plasmincatalyzed digests, in that Aa-chain fragmentation precedes that of B,8-chain. The addition of plasminogen activators to plasma induced an increase in the N-atosyl-L-arginine methyl ester HCl esterase and fibrinogenolytic activity associated with a2-macroglobulin purified from this plasma, indicating that the enzymic activity of the complex was preserved and could be increased in the presence of other plasma enzyme inhibitors. Immunochemical studies demonstrated that an a2-macroglobulin-plasmin complex had formed in urokinase-treated plasma. This a2-macroglobulin preparation manifested an esterolytic profile like that of a complex prepared from plasmin and purified a2-macroglobulin. After complex formation with a2-macroglobulin in plasma, plasmin retained less than 0.1% of its fibrinogenolytic activity. That plasmin expressed its activity while bound to a2-macroglobulin was suggested by immunoprecipitation of this activity with aa-macroglobulin antibody and by the demonstration that pancreatic trypsin inhibitor did not effectively inhibit its fibrinogenolytic or esterolytic activity. These results raise the possibility that, in addition to its activity as a major plasma proteolytic enzyme inhibitor, a2-macroglobulin may modThis paper was presented in part at the 15th Annual Meeting,
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INTRODUCTION
The role that circulating enzyme inhibitors play in modulating the interactions involved in hemostatic and inflammatory processes is not well understood. One such inhibitor, plasma a2-macroglobulin, apparently participates in the regulation of several different plasma enzyme systems, since it has been shown in vitro to form a complex with plasmin (1-3), thrombin (4) (5) (6) , and kallikrein (7) (8) (9) , resulting in inhibition of proteolytic activity. In contrast, the ability of these enzymeinhibitor complexes to degrade synthetic amino acid ester substrates (esterolytic activity) is only slightly modified, demonstrating that the catalytic potential of the bound enzyme is retained.
Circulating human fibrinogen consists of a heterogenous family of coagulable species identifiable by solubility characteristics ranging in molecular weight from that of "native" fibrinogen, 325,000 (e.g., fraction I-4) to 261,000 (e.g., fraction I-9) (10) (11) (12) . Turnover studies in rabbits have shown a classical precursorproduct relationship between high and low molecular weight forms of isotopically labeled fibrinogen (13) . Increased amounts of low molecular weight forms of fibrinogen have been shown in patients receiving urokinase therapy (13) . These observations have provided conclusive support for the hypothesis (10) they had not been acted upon by throimibin (11, 12) . Furthermore, the suggestion that the reduction in molecular size wvas the consequence of cleavage of peptide material from the COOH-terminal region of the core imiolecule (10, 11) has been confirimied (12) and extended by the demonstration that uinder physiologic circumstances such attack appears to be conifined to the Aa-chains (12, 14) . Sinillarities between the plasmna catabolites and early fibrinogen derivatives resulting from plasmin-catalyzed hydrolysis (14) (15) (16) (17) (18) Hutman plasma as-macroglobulin was prepared from venous blood freshly collected from normal individuals into l Abbreviatioiis utsed in this paper: AGLMe, N-a-acetylglycyl-L-lysine methyl ester acetate; ALMe, N-a-acetyl-Llysine methyl ester HCl; BAMe, N-benzoyl-L-arginine methyl ester HCI; DTT, dithiothreitol; SDS, sodium dodecyl sulfate; TAMe, A-a-tosyl-L-arginine methyl ester HCl. plastic containers to minimize activation of Hageman factor (Factor XII). The plasma was harvested after centrifugation at 2000 g for 15 min at 4°C. The anticoagulant used contained soybean trypsin inhibitor (0.5 mg/ml of 3.8% sodium citrate), unless subsequent incubation with plasminog-en activators was planned. For these latter experiments plasma was incubated w\ith urokinase at a final concentration of 100 U or 500 U/mi, or with streptokinase, 500 U/ml, for 1 h at 37°C, before the addition of soybean trypsin inhibitor to a final coincenitration of 0.1 mg/mil. Soybean trypsin inhibitor in this concenitratioin was also added to buffers used in the chromatographic procedures. In some preparations, Polybrene (25 Ag/ml, final concentration), an inhibitor of Hageman factor activation (19), or 0.1 M c-anminocaproic acid in addition to soybean trypsin inhibitor -as adcled to tlle anticoagulant and subsequent buffers. a2-Macroglobulin was prepared from these plasma samples by the following procedures, described previously in detail (7) . After initial adsorption with barium chloride anid barium sulfate, and i )recipitation with polyethylene glycol, the preparation w-as subjected to gel filtration chrom:itography andI Pevikon block electrophoresis (Kema Nord, Stockholm, Sweden). The final product, by immunoelectrophoretic analysis, formed a single precipitin arc against rabbit whole antihuman serumll (20) and was identified as a2-macroglobulin using specific antiserum.
The humianl fibrinoyen) used had been rendered plasminogen-free by precipitation (21) and was further purified by DEAE-cellulose column clhromatograplhy (22 Estcrolltic assays using (lifferent amino acid methyl ester substrates at a final concentration of 0.015 M were carried out as previously described (26) .
Fibrinogem and the various purified a2-macroglobulin preparations were incubated at 37°C in the concentrations detailed in the figure legends. Portions of the incubation mixtures were removed at intervals and heated for 10 min at 56-61°C to precipitate the fibrinogen, which was then dissolved and reduced in a solution of 10 M urea, 1% SDS and 14 mM DTT for 45 min at 37°C. Alternatively, the incubation mixture was added to this solution directly. The samples were analyzed by SDS-polyacrylamide gel electrophoresis (9% gels) as described by Weber and Osborn and were stained with coomassie brilliant blue (27 Electroimmnttoanalysis of the a2-macroglobulin preparations was performed in agarose gels containing plasminogen antiserum (1% vol/vol) at 40 V/cm for 1 h as described by Laurell (28, 29) and as applied to the plasmin-rich a2-macroglobulin preparations by Nil6hn and Ganrot (30) .
Quanttitation of the fibrinogenolytic actizity of a8-macroglobulin preparationts. Approximate quantitative estimates of the fibrinogenolytic activity of a2-macroglobulin preparations were made from comparison of the degree of hydrolysis of fibrinogen rendered by known amounts of plasmin and of a2-macroglobulin. The means selected for achieving this estimate was comparison of the band pattern of SDS-polyacrylamide gels of samples from fibrinogen digests. In these comparisons, the time required to reach a selected degradative pattern was noted (viz., time for plasmin versus time for a2-macroglobulin). The results were then converted to caseinolytic units per milligram of a2-macroglobulin by extrapolation. For example, if plasmin at a concentration of 1 X 10-2 caseinolytic U/ml required 15 min to achieve a given gel pattern of degradation, and a2-macroglobulin required 24 h to achieve the same degree of degradation, the caseinolytic activity of the a2-macroglobulin-enzyme complex was approximately 1 X 10' caseinolytic U/mg a2-macroglobulin.
Inimtntoprecipitation studies were performed by adding 6 mg of the IgG fraction of a2-macroglobulin antiserum to an equal amount of a2-macroglobulin from urokinase-treated plasma (500 U/ml plasma), or adding 0.15 M NaCl to the a2-macroglobulin control in place of the antibody preparation. After incubation for 30 min at 37°C and then overnight at 4°C, the precipitate was removed by centrifugation for 10 min at 3,000 rpm (9) . Polyethylene glycol (molecular weight 6,000) was added to the supernate (final concentration 15%), and the precipitate was resuspended in 1.0 ml buffer. The immune-absorbed sample contained no a2-macroglobulin as assayed by single diffusion analysis, whereas the control specimen contained 5.6 mg. These preparations were incubated with fibrinogen, and alterations in the subunit chains of fibrinogen were assessed by SDSpolyacrylamide gel electrophoresis.
RESULTS
The effect of urokinase and streptokinase on the TAMe esterase activity associated with1 humtan plasma as-macroglobulin (Table I) . a2-Macroglobulin, prepared from platelet-poor human plasma, processed entirely in plastic containers in the presence of soybean trypsin inhibitor, was associated with a low level of TAMe esterolytic activity, a finding previously reported (7) and extended in this study to * The a2-macroglobulin was prepared as described in Xlethods.
The TAMe esterase activity of the a2-macroglobulin preparations was measured in the presence and absence of pancreatic trypsin inhibitor (100 ,ug/ml, final concentration). Plasmin (two preparations), tinder the conditions of this experiment, hydrolyzed 28.2 JAmol TAMNe/caseinolytic U/h; this activity was completely inhibited by pancreatic trypsin inhibitor. preincubated with urokinase possessed greatly enhanced TAMe esterase activity and the increase in activity was commensurate with the final concentration of urokinase. A plasma urokinase concentration of 100 U/ml resulted in a 15-fold increase in TAMe esterase activity, whereas a2-macroglobulin obtained from plasma incubated with 500 U urokinase/ml demonstrated a 40-fold increase in activity. The possibility that the esterolytic activity associated with the a2-macroglobulin from urokinase-treated plasma was due to an a2-macroglobulinurokinase complex was eliminated bv the following control experiment. A 10-min incubation mixture of a2-macroglobulin purified from untreated plasma (6.5 mg) and urokinase (500 U) was applied to a Sephadex G-75 column (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.). The TAMe esterase activity of the a2-macroglobulin fractions was identical to the activity of the control a2-macroglobulin preparation. The TAMe esterase peak associated with the urokinase preparation was completely separated from the a2-macroglobulin fractions by this procedure. Streptokinase, which has no intrinsic esterase activity, produced an enhancement in a2-macroglobulin-associated esterase activity similar to that obtained after the addition of urokinase to plasma. Though pancreatic trypsin inhibitor (100 ig/ ml) completely inhibited the TAMe esterase activity of plasmin, it failed to inhibit the esterolytic activity of a2-macroglobulin preparations studied. Soybean trypsin inhibitor was equally ineffective.
The hydrolysis of substituted arginine and lysine methyl esters by plasnzin, by an as-nacroglobulin-plasFibrinogen Degradation by a2-Macroglobulin The binding of plasmin to a2-macroglobulin as determined by the ability of increasing concentrations of a2-macroglobulin to protect the TAMe esterase activity of a constant concentration of plasmin from inhibition by soybean trypsin inhibitor. Dilutions of a2-macroglobulin were added to human plasmin (0.2 caseinolytic U). After 1 min preincubation, 100 jug soybean trypsin inhibitor was added, and the mixture was incubated with TAMe. The data in the upper graph are plotted to indicate the capacity of a2-macroglobulin to protect bound plasmin against inhibition by soybean trypsin inhibitor. The data in the lower graph are plotted to indicate the specific activity of a2-macroglobulin.
suggested that proteolytic enzymes could be identified by the rates at which they catalyze the hydrolysis of different synthetic esters (31) (32) (33) . a2-Alacroglobulin prepared from urokinase-treated plasmiia had a hydrolytic p)rofile similar, but not identical, to that found for the a2-macroglobulin-plasmin complex, suggesting that plasin or plasmiiin-like activity was bound to this a2-macroglobulin. On the other hand, though the observed ratio of the plasmin-catalyzed hydrolysis of BAMle, AL'Me, and AGLAMe relative to that of TAMe was characteristic for the free enzyme (32) , the profile differed markedly fronm that of the a2-macroglobulin-plasin comlplex. Tlhis was clearlv apparent in the impaired ability of the comlplex to hydrolyze BAMIe, ALMe, and AGLMIe, and onl this basis, permits the conclusion that plasmini bound to a2-macroglobulin has anl altered substrate specificity.
Immu.n1ltologic identificationi of a plasninii-rclated antiget comiiplexed to a2-mtacroglobidnun prepared fromn u rokinase-treated plasmia (Fig 1) . Precipitin arcs witlh similar electrophoretic mobilities formiied after immunoelectrophoresis (20) of a2-macroglobulin from urokinasetreated plasma against antisera to human plasminogen or a2-mnacroglobulin (Fig. 1, top slide) . Purified human SDS-polyacrylamide gel electrophoresis of subunit chains of heat-precipitated fibrinogen after. incubation with a2-macroglobulin (a2-M) preparations. a2-Macroglobulin (4.8 mg/ml), prepared from untreated plasma or from plasma incubated with 100 or 500 U urokinase/ml or 500 U streptokinase/ml, was incubated at 370C with fibrinogen (1.6 mg/ml) in 0.025 M Tris-HCI buffer, pH 7.5, containing 0.16% sodium citrate and 0.85%o sodium chloride. Samples were removed at 0, 6, 24, and 48 h and the fibrinogen precipitated by heating. The precipitate was then redissolved in an SDS urea solution and reduced by treatment with DTT before acrylamide gel electrophoresis. From left to right, fibrinogen incubated with a2-macroglobulin from untreated plasma, gels 1, 2, and 3; from plasma treated with 500 U urokinase/ml, gels 4, 5, and 6; from plasma incubated with 100 U urokinase/ml or with 500 U streptokinase/ml, gels 7 and 8, respectively. plasminogen or urokinase-activated plasniin produced precipitin arcs similar to those described previously (34) (Fig. 1, lower slide) but differing in their electrophoretic mobilities from the a2-macroglobulin associated plasminogen-related antigen. Since the antigenic properties of plasmin and plasminogen are the same (34) , these findings suggest that in the samples tested, plasmin is complexed with a2-macroglobulin and is the enzyme responsible for the esterolytic activity demonstrated in Table I .
Electroimmunoassay utilizing agarose gel containing plasminogen antibody (28) (29) (30) confirmed the presence of a plasmin-related antigen in a2-macroglobulin from urokinase-treated plasma and permitted a semi-quantitative analysis of the lower limit of detectability of such an antigen by this technique. The lowest concentration of this a2-macroglobulin sample that formed an immunoprecipitate was 0.6 mg/ml (20-fold dilution of the sample shown in Fig. 1 ). Though a2-macroglobulin from untreated plasma failed to show immunoreactivitv in this system at a protein concentration as high as 18 mg/ml, the 40-fold difference in the TAMe esterase activity (Table I) suggested that the enzymic activity in the untreated a2-macroglobulin sample, even if attributable to plasmin, was too low to have been identified by this immunochemical method.
The binding capacity of at-macroglobulin for human plasmin (Fig. 2) . The residual TAMe esterase activity of a mixture of a2-macroglobulin and plasmin, after the addition of plasmin inhibitors (e.g., pancreatic or soybean trypsin inhibitor) reflects the plasmin that has been bound to a2-macroglobulin and thereby protected from inhibition (3) . Since the addition of a2-macroglobulin to plasmin does not inhibit its TAMe esterase activity (Table II) , such activity in the presence of a plasmin inhibitor can be used to measure a2-macroglobulin-bound plasmin directly.
Based upon these considerations, the following experimental design was employed. After an incubation period of 1 min to allow for complex formation between a2-macroglobulin and plasmin, soybean trypsin inhibitor was added. By comparison of specific activity (Fig. 2 , lower graph) and esterase activity (Fig. 2 inspection of the gels, as illustrated in Fig. 3 , as well as from densitometric scans (Fig. 4) (12, 35) . The earliest and ultimately mlost extensiv-e clhange was depletion of the intact Aa-chain position. Accomlpanying this, but at a slower rate (clearly evident in the densitomiietric scans) Nwas a depletion of the intact Bj3-chain position and the appearance of a Bg-chain derivative, termed /13-1 (36) , whicl appeared in more extensively degraded samples (e.g., Fig. 3 . gels [6] [7] [8] . The /0-1 chain migrates in a positioln intermiiediate to that of intact B13-and a-chains (12, 15, 37) . Since this chain was oftein indistinct or not well resolved by the densitometric scan, its scan area was included in computation of the "intact' B1-clhain positioIn. Thus, the calculationi of depletion of the B13-position in 24-and 48-h samples of urokinase-or streptokinase-treated a2-macroglobulin was somewhat underestimatedl.
Compared with the proteolytic activity of a2-nmacroglobulin from plasma, a far mlore extensive degradationi of fibrinogeni structure occurred in a2-macroglobulin obtained froml urokinase-or streptokinase-treated plasma.
The fibrinogenolytic activity of the a2-macroglobulin fronl urokinase-treated plasma (100 or 500 U nml) was coImlmlelnsurate with the amount of urokinase added. Fibrinogen incubated with buffer or with urokinase alone showed no appreciable change in its subunit structure under the same experimental conditions, indicating that the structural changes that did occur were attributable solely to the proteol-tic activity associated with the a2-macroglobulin. Incubation of the a2-macroglobulin preparationis wvith urokinase failed to enhaince their fibrinogenolytic activity, demonstrating the absence of detectable plasmlinogen.
To express the fibrinogenolytic potential of a2-m1acro-globulin preparations in quantitative terms, a comparisoIn was made between a selected degree of fibrinogen degradation catalyzed by known amounts of free plasmin and by a2-macroglobulin. The time required to achieve that degree of degradation (viz., time for plasmin com- treated plasma had an activity 3-5 times greater. In comparison with the amount of plasmin estimated to be bound to this preparation (i.e., 0.7 caseinolytic U/ mg a2-macroglobulin), the fibrinogenolytic potential of bound plasmin had been reduced to less than 0.1% of that of an equivalent amount of the free enzyme.
The effect of pancreatic trypsin inhibitor and e-aminocaproic acid on the proteolysis of fibrinogen by plasmin or by aa-macroglobtlin-enzyme comBplexes (Fig. 5) .
Incubation of plasmin (0.07 caseinolytic U/ml) with fibrinogen resulted in extensive degradation of the subunit chains of fibrinogen within 10 min at 370C (not shown). Pancreatic trypsin inhibitor (20 ,ig/ml) added to fibrinogen effectively inhibited this reaction as assessed by the 24-h sample (Fig. 5, gel 1) . In sharp contrast, a2-macroglobulin from urokinase-treated plasma caused extensive degradation of fibrinogen chains even in the presence of pancreatic trypsin inhibitor (gels 2, 3, and 4),-though the preparations containing the inhibitor were somewhat less degraded. Thus, pancreatic trypsin inhibitor had only a slight effect in modifying the proteolytic activity of a2-macroglobulin complexes. Parallel studies with e-aminocaproic acid at concentrations of 0.1 Mv1 confirmed previous observations (38) that this agent is not an effective inhibitor of plasmin. Consistent with this, a2-macroglobulin-mediated degradation of fibrinogen was also not effectively inhibited by e-aminocaproic acid.
The effect of itmnunoprecipitation upon the fibrinogenolytic activity associated with as-mnacroglobulin preparations (Fig. 6 ). To provide even stronger evidence that all detectable fibrinogenolytic activity was closely associated with a2-macroglobulin, the relationship of a2-macroglobulin to its proteolytic activity was further explored by immunoprecipitation. An IgG fraction, itself possessing no antiplasmin activity as demonstrated by a fibrinolytic assay (39) , having antibody specific for a2-macroglobulin, was added in optimal amounts (40) to the a2-macroglobulin prepared from urokinasetreated plasma. After removal of the precipitate which formed after an 18-h incubation at 40C, the supernatant fluid contained no detectable a2-macroglobulin as determined by electroimmunoanalysis (28) . In contrast to the extensive fragmentation of fibrinogen rendered by the a2-macroglobulin starting material, the supernatant fluid, depleted of a2-macroglobulin, had lost its fibrinogenolytic potential as well.
sequence of degradation is similar to that observed in plasmin-catalyzed digests, in that Aa-chain fragmentation precedes that of BP-chain (12, (14) (15) (16) (17) (18) Fibrinogen Degradation by a2-Macroglobulin 2181 globulin fromi urokinase-treated plasilma (500 U urokinase/ml plasmiia). Less than 0.1% of this plasimin was expresse(c as fibinogenolvtic activity. These data provide in quantitative termls a confirmlation of the conclusion drawn by several previous investigators, that a2-macroglobulin is a miiore effective inhlibitor of proteolytic than of esterolytic activity (3, 4, 41 (46, 47) infusion. Nil6hn and Gainrot (30) have shown the formation of an a2-macroglobulin-p)lasniin complex after streptokinase infusioin by inmmlunioclhelmiical teclhniques. These results have been extende(d in the present study by the demonstrationi thalt the addition of urokinase or streptokinase to plasmla resulted in enhlainced fibrinogenolytic and esterolytic activity associated with the a2-macroglobulin ultimately purifiecl froml this incubation mlixture, and by the subsequenit identificatioin, as outlined, of the enzymle responsible for this activity as plasnin.
The data fromli tlis studv strongly suggest that a2-nacroglobuliin-enzymne comiplexes possess fibrinogeniolytic activity that cannot be due to free enzyme. This proteolytic activity is closely associated with the high molecular weight complex itself, as evidenced by the observation that pancreatic try psin inhibitor, whei added to fibrinogein completely inhibited the proteolytic activity of fee plasmiin but failed to prevent the degradation of fibrinogen by the Ca2-nmacroglobulin preparationis. Furtherinmore, immlilunopr-ecipitation of a2-macroglobulin by specific antiserumii renmoved the a2-macroglobulin and its fibrinogenolytic activity. Several other investigators have concluded that a2-m1acroglobul in-enzyme complexes produced their proteolytic effect by a dissociation of the enzynme from the complex (30, (48) (49) (50) 
